Merck Collaborates with Dragonfly to Develop and Commercialize Novel Therapies Utilizing TriNKET Platform
Shots:
- Dragonfly to receive ~ $47.5M up front- equity investment- development & commercial milestones along with royalties on sales of approved therapies
- Merck to get an option to license exclusive IP rights for multiple candidates developed using Dragonfly's TriNKET technology platform for new targets in oncology- infectious disease- and immune disorders
- Dragonfly's TriNKET technology act by harnessing the body's innate immune system to bring breakthrough cancer therapies to the patients
Click here to read full press release/ article
Ref: PRNewswire | Image: Merck
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com